Allergic Bronchopulmonary Aspergillosis in Asthma and Cystic Fibrosis
Author Information
Author(s): Alan P. Knutsen, Raymond G. Slavin
Primary Institution: Saint Louis University
Hypothesis
ABPA develops in genetically susceptible individuals with asthma and CF due to increased frequency and/or activity of A. fumigatus-specific Th2 CD4+ cells.
Conclusion
Early diagnosis and treatment of ABPA are essential to prevent permanent lung damage.
Supporting Evidence
- ABPA affects approximately 1-2% of asthmatic patients and 7–9% of CF patients.
- Genetic risks for ABPA include HLA-DR and HLA-DQ polymorphisms.
- Treatment with systemic corticosteroids is essential for managing ABPA.
Takeaway
Some people with asthma and cystic fibrosis can get a lung disease called ABPA from a mold. If caught early, it can be treated to avoid serious lung problems.
Methodology
The article reviews genetic risks, immunopathogenesis, diagnosis, and treatment of ABPA.
Limitations
The diagnosis of ABPA in cystic fibrosis is complicated due to overlapping symptoms.
Participant Demographics
The study focuses on patients with asthma and cystic fibrosis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website